Abeome launched a stem-cell mAb for distribution through Millipore. Under the agreement, Millipore is granted an exclusive, worldwide license to market and distribute the antibody for research use.


This initial antibody was developed by Abeome in collaboration with Novocell. The antibody’s target is a cell surface protein that may prove to be a unique and important antigen, according to Abeome. The target protein appears to be present on five human embryonic cell lines but does not appear to be expressed on most differentiated cell types or common feeder cells.


Scientists will use this antibody to help identify specific cell types that may be important in cancer therapeutic and diagnostic research.